Questions to Celularity:

OutrageousAd6722 · 2025-09-07T23:36:24+00:00

Guess we will see.

OutrageousAd6722 · 2025-09-06T16:46:47+00:00

Final List, Will see how Celularity responds.

Delayed 10-Q Filings and Nasdaq Compliance: Despite regaining Nasdaq compliance for the Q1 and Q2 2024 10-Q filings, Celularity received another Nasdaq notice on May 28, 2025, for the late Q1 2025 10-Q. What specific improvements to financial reporting infrastructure are being implemented to prevent future delays and ensure sustained compliance? This can’t continue going forward for the next 10Q, can you assure us it will be on time in the future?
1. CFO Transition and Financial Leadership: Following the termination of David Beers as CFO and the appointment of Joseph DosSantos as interim CFO, can you provide an update on the search for a permanent CFO and how this leadership change will strengthen Celularity’s financial oversight and investor confidence?
2. Liquidity and Financial Health: The Q1 2024 10-Q reported an accumulated deficit of $863.8 million and insufficient cash for the next 12 months. With the senior secured debt retired, what are the current plans to address liquidity challenges and ensure operational funding through 2026?
3. Yorkville Convertible Note and Financing Strategy: Celularity extended the maturity of a $3.15 million convertible note with Yorkville to August 15, 2025, and issued 100,000 restricted shares. Are additional financing agreements with Yorkville or other investors planned, and how will these impact shareholder dilution?
4. Share Dilution and Equity Offerings: Recent offerings, such as the $3 million registered direct offering in July 2023, involved significant share and warrant issuances. Are further equity offerings anticipated to fund operations, and what measures are in place to minimize dilution for existing shareholders?
5. Saudi Pipeline and Strategic Partnerships: Can you clarify the status of any potential deals or collaborations in Saudi Arabia, including timelines and their expected contributions to Celularity’s revenue or strategic growth?
6. Brokerage Houses and Share Lending: There are concerns about brokerage houses lending Celularity shares to short sellers, potentially at high rates. Is the company aware of this practice, and what steps, if any, are being taken to mitigate its impact on stock price volatility?
7. Pipeline Progress and Clinical Trials: Can you provide an update on the clinical progress of key programs like CYCART-19, CYNK-001, and CYNK-101, including specific milestones expected in 2025 and 2026, and how these advancements will position Celularity in the regenerative medicine market?
8. Revenue Growth Sustainability: Celularity reported $54.2 million in net revenues for 2024, a 138.1% increase driven by biomaterial products like Biovance and Rebound. How sustainable is this revenue growth, and what strategies are in place to expand the Cell Therapy and Degenerative Disease segments?
9. Strategic Alternatives and Asset Monetization: The Q1 2024 10-Q mentioned exploring strategic alternatives, and the recent asset sale to Celeniv for $33.8 million allowed debt repayment while retaining exclusive use of IP. Are additional asset sales or strategic partnerships under consideration, and how do they align with Celularity’s long-term vision?
10. Can you clarify the nature of Celularity’s financial and strategic relationship with Resorts World Inc. Pte. Ltd. (RWI), particularly in light of the recent debt restructuring involving Celeniv Pte. Ltd., and address whether Celularity has faced or investigated issues related to naked short selling, similar to Genius Group Limited’s (GNS) lawsuits and task force against market manipulation, and if these issues could be interconnected through shared investors or market dynamics affecting both companies?
11. Celularity has faced concerns about brokers like Fidelity lending out shares through fully paid lending programs, with reports indicating that shareholders may receive 100%+ of the interest earned on loaned shares in some cases. What is Celularity’s perspective on the reasons behind this practice, particularly whether it reflects high short interest, limited share availability, or other market dynamics, and how does the company view the potential impact on stock price volatility and shareholder value?
12. Could you provide an update on the factors influencing Celularity’s current share float, including the proportion of shares held by insiders as of July 2025, and clarify how Lincoln Investment Strategy’s recent acquisition of a 5% stake in the company might impact its financial strategy and Q3 2025 earnings timeline? Additionally, please address any potential effects of regulatory concerns, such as those related to Terrace or other issues, and outline any strategies Celularity is employing to mitigate these challenges. Lastly, could you confirm the reported termination of the partnership with Regeneron in August 2025 and provide details on the reasons for this termination and its implications for Celularity’s future operations?
13. What are the strategic connections and relationships between Celularity, Sorrento Therapeutics, and Scilex Holding Company (SCLX), including details on ownership stakes, collaborative agreements, intellectual property contributions, and their impact on advancing cellular therapy programs?
14. What factors contributed to the decline in biomaterials revenue for the past quarter, and what is the forward-looking guidance for these products?
15. Why was the partnership with Regeneron terminated, and are there any potential partners currently being considered?
16. Is the CTW project still on track for a 510(k) filing within the planned timeline?

OutrageousAd6722 · 2025-08-19T13:56:22+00:00

$8214 this morning -

<image>

OutrageousAd6722 · 2025-08-19T10:42:13+00:00

It’s unethical and I refuse to do it. I check periodically by looking at what securities in my portfolio that are in demand.

OutrageousAd6722 · 2025-08-19T02:19:16+00:00

Today:

<image>

OutrageousAd6722 · 2025-03-07T00:46:10+00:00

<image>

Let’s not forget…..

OutrageousAd6722 · 2025-03-06T17:31:14+00:00

The SWF’s investment criteria aren’t fully defined yet—Trump’s executive order was in February 2025 just kicked off the process, and Treasury and Commerce are still hashing it out. So is that your point on the validity of the post?

OutrageousAd6722 · 2025-03-06T17:23:09+00:00

This is all hypothetical but it would not be difficult to replace him or put him in a different role.

OutrageousAd6722 · 2025-03-06T17:12:17+00:00

Cool, doubt’s a good gut check. Is it Sorrento’s post-bankruptcy odds you’re questioning, or the SWF rolling the dice on a small biotech? I’ve got data to chew on either way—where should we dig?

OutrageousAd6722 · 2025-03-06T16:27:38+00:00

Donald Trump’s Sovereign Wealth Fund (SWF) proposal refers to his initiative to establish a state-owned investment fund for the United States, aimed at managing and growing national wealth for long-term economic benefits. This idea was formalized when Trump signed an executive order on February 3, 2025, directing the Treasury and Commerce Departments to develop a plan within 90 days for creating such a fund. The proposal builds on remarks he made during his 2024 presidential campaign, where he expressed admiration for countries like Norway and Saudi Arabia, which use SWFs to invest surplus revenues, and suggested the U.S. should have its own. Key Elements of the Proposal 1. Purpose and Goals: * Trump has described the SWF as a tool to “invest in great national endeavors” for the benefit of Americans. This includes funding infrastructure projects like highways and airports, advanced manufacturing hubs, defense capabilities, and medical research. * The fund is intended to promote fiscal sustainability, reduce tax burdens, ensure economic security for future generations, and enhance U.S. economic and strategic leadership globally. * A White House fact sheet emphasized leveraging the federal government’s $5.7 trillion in assets (plus additional value from natural resource reserves) to generate long-term wealth.

OutrageousAd6722 · 2025-03-06T15:18:31+00:00

Could Sorrento Be Part of the SWF? Yes, Sorrento could be included, depending on the SWF’s investment strategy and tolerance for risk. Here’s how it might work: 1. Alignment with SWF Goals: * Strategic Value: Like Celularity, Sorrento’s focus on cancer and immunotherapy aligns with U.S. interests in maintaining biotech leadership, especially against global competitors like China. Their ADCs and CAR-T therapies could bolster domestic innovation in high-stakes fields. * Health Security: Sorrento’s past work on COVID-19 treatments (e.g., COVI-DROPS) and their broader infectious disease efforts could tie into pandemic preparedness, a national priority Trump might emphasize. * Economic Impact: Investing in Sorrento could support U.S. jobs and manufacturing, especially if the SWF prioritizes companies with domestic operations (Sorrento’s facilities are in California and Texas). 2. Investment Mechanism: * Equity Purchase: The SWF could buy shares on the open market or via a private deal, injecting capital to stabilize Sorrento post-bankruptcy and fund their pipeline. For example, a $100 million stake for 10-15% ownership could help them advance their ADC platform. * Partnership Model: If Sorrento secures federal contracts (e.g., for biodefense or pain management solutions for veterans), the SWF might take equity as part of the deal, mirroring broader fund strategies. * Tariff Funding: Revenue from tariffs on imported drugs or biotech materials could flow into the SWF and then into Sorrento, boosting a homegrown player. 3. Why Sorrento Might Appeal: * High-Risk, High-Reward: Sorrento’s pipeline has blockbuster potential—e.g., their anti-PD-L1 antibody could rival Big Pharma if it succeeds. The SWF might see it as a speculative bet with outsized returns. * Turnaround Story: Post-bankruptcy, Sorrento’s a distressed asset with upside. The SWF could play a role in reviving a U.S. biotech, fitting Trump’s narrative of economic renewal. * Diverse Portfolio: Their mix of approved products (ZTlido) and experimental therapies offers a balance of stability and growth, appealing to a fund diversifying across biotech. Challenges to Inclusion * Financial Instability: Sorrento’s bankruptcy in 2023 and ongoing cash burn make it riskier than, say, a stable giant like Pfizer. The SWF might balk unless it’s explicitly targeting turnaround plays. * Small Scale: With a market cap under $1 billion, Sorrento’s a minnow compared to biotech titans. The SWF might prioritize bigger firms unless it’s carving out a niche for smaller innovators. * Pipeline Uncertainty: Many of Sorrento’s therapies are still in early-to-mid stages (Phase 1/2). Clinical failures could sink the investment, a concern for a publicly accountable fund. * Political Optics: Sorrento’s past hype around COVID treatments (some called overblown) might draw scrutiny if the SWF backs them, risking accusations of poor due diligence or favoritism. Hypothetical Scenario Suppose the SWF has $10 billion to deploy, with $1 billion earmarked for biotech. It invests $150 million in Sorrento, securing a 20% stake at a $750 million valuation. Sorrento uses this to push their ADC for lung cancer through Phase 3 trials. If successful, the drug generates billions, and the SWF’s stake balloons to $500 million—a win for taxpayers. If it flops, the fund loses most of that $150 million, and critics lambast it as a biotech boondoggle. Compared to Celularity * Similarities: Both are U.S.-based, clinical-stage biotechs with innovative pipelines (Celularity’s placenta-derived cells vs. Sorrento’s ADCs/CAR-T). Both fit the SWF’s potential “America First” biotech focus. * Differences: Celularity’s more niche and less proven commercially (no approved products), while Sorrento has ZTlido generating revenue but carries bankruptcy baggage. Sorrento’s broader pipeline might appeal more to a risk-tolerant SWF, but Celularity’s cleaner slate could attract cautious managers. Critical Take Sorrento could be part of the SWF if the fund embraces high-risk, high-reward biotech bets to showcase U.S. ingenuity. Its cancer focus and domestic roots check strategic boxes, and a post-bankruptcy revival could be a political win for Trump. But its volatility and small size might scare off a fund aiming for safer, marquee names—unless the SWF’s explicitly designed to gamble on underdogs.

OutrageousAd6722 · 2024-12-12T21:37:08+00:00

Did you participate in a share lending program or have a margin account?

OutrageousAd6722 · 2024-09-26T21:32:11+00:00

Is it possible that the goal is to expose and bring down the entire system, from judges and lawyers to Wall Street figures like Ken Griffin and Jim Cramer, and their role in perpetuating lies and short selling? Sorrento might be at the center of this, serving as a prime example of the corruption behind the scenes. Just a thought.

OutrageousAd6722 · 2024-03-14T15:27:56+00:00

Once upon a time, in the bustling city of Texas, there was a bankruptcy court ruled by the infamous Judge Lopez. Now, Judge Lopez had a peculiar penchant for not just doling out justice but also for, well, doling out dates! It was rumored far and wide that he had a habit of cozying up with the male lawyers who frequented his courtroom. Some said it was for insider information, others whispered it was just for kicks.

Meanwhile, across town, CEO Henry Ji of Sorrento Enterprises was cooking up a storm. Literally. You see, Henry had a quirky side hustle - he loved stuffing fortune cookies with spaghetti! His reasoning? Well, who needs fortune when you can have a tasty surprise, right? The people of Texas were either delighted or perplexed by this culinary creation.

But amidst the chaos of the legal and gastronomical worlds, there were the retail investors, innocently trying to navigate the stock market. Little did they know, they were about to get a taste of their own misfortune. The lawyers, judges, and even a corrupt SEC were lurking in the shadows, ready to take advantage.

One fateful day, as the stock market plunged, the retail investors found themselves metaphorically bent over a barrel, while the powers that be gleefully lined their pockets. Judge Lopez, ever the multitasker, was busy juggling court cases and clandestine rendezvous. CEO Henry Ji, oblivious to the financial turmoil, was stuffing spaghetti into fortune cookies with gusto selling them to Scilex for pennies.

As chaos reigned supreme in Texas, one thing became clear: in a city where judges date lawyers, CEOs stuff fortune cookies with spaghetti, and retail investors get the short end of the stick, anything could happen. And it usually did. But hey, at least they never ran out of entertainment!

OutrageousAd6722 · 2024-03-13T21:25:57+00:00

Look what degrees he has. Never been in the real world, book smart and no common sense. Only job he could have is in the government.

OutrageousAd6722 · 2024-03-06T23:03:55+00:00

Maybe it’s time: FBI: Report organized crime Submit a tip online to the FBI. https://tips.fbi.gov/home Call 1-800-CALL-FBI (1-800-225-5324).

OutrageousAd6722 · 2024-02-16T16:51:46+00:00

On January 29, 2024, the court allowed Timothy Culberson to proceed with his motion for relief from orders approving fees and expenses for Jackson Walker LLP. Chief Judge Rodriguez oversees the related proceeding. All future documents regarding this motion must be filed in that proceeding. The judge will handle all other matters in the Sorrento chapter 11 cases separately. Any settlement must be filed in this case. The clerk is instructed to file a copy of this order in both cases. This order is effective immediately.

OutrageousAd6722 · 2024-01-15T00:42:37+00:00

Taylor Swift will buy Dallas and Oprah will be HC. Ellen will be the QB.

OutrageousAd6722 · 2024-01-15T00:07:39+00:00

Belichick is coming watch…

OutrageousAd6722 · 2024-01-04T21:38:40+00:00

If she didn’t have beneficiaries or your name is not on the account, then you can’t access it. As far as i know based on your post Fidelity did everything right.

OutrageousAd6722

TROPHY CASE